SG/CALL/BRISTOL-MYERS SQUIBB/85/0.1/17.01.25

SG/CALL/BRISTOL-MYERS SQUIBB/85/0.1/17.01.25 Share Price

DE000SQ86UH5

Delayed Deutsche Boerse AG 01:23:53 07/06/2024 pm IST
0.001 ^EUR	0.00%

6 months	-94.12%
Current year	-95.24%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/85/0.1/17.01.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06	MT
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma	05/06	AQ
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06	CI
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	04/06	MT

More news

Quotes 5-day view

Date	Price	Change
07/24/07	0.001	0.00%
06/24/06	0.001	0.00%
05/24/05	0.001	0.00%
04/24/04	0.001	0.00%
03/24/03	0.001	0.00%

Delayed Quote Deutsche Boerse AG

Last update June 07, 2024 at 01:23 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SQ86UH
ISIN	DE000SQ86UH5
Date issued	16/02/2023
Strike	85 $
Maturity	17/01/2025 (225 Days)
Parity	10 : 1
Emission price	0.54 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.5 €
Lowest since issue	0.001 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	0x
Moneyness	0.4809
Difference Strike	44.12 $
Difference Strike %	+51.91%
Intrinsic value	0.000000

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

40.88 USD

Average target price

53.19 USD

Spread / Average Target

+30.12%

Consensus